Navigation Links
PLC Systems Signs TMR Asset Sale Agreement with Novadaq
Date:11/8/2010

FRANKLIN, Mass., Nov. 8, 2010 /PRNewswire-FirstCall/ -- PLC Systems Inc. (OTC Bulletin Board: PLCSF), a company focused on innovative medical device-based technologies, today announced that it had signed a definitive agreement to sell all of its Transmyocardial Revascularization (TMR) assets to Novadaq Technologies Inc. (TSX: NDQ), a developer of real-time imaging systems for use in the operating room. Novadaq has been the exclusive United States distributor of PLC's CO2 Heart Laser Systems and related kits for TMR since March 2007.

Under terms of the agreement, Novadaq will acquire all of PLC's assets in the TMR business including manufacturing rights, product inventories, equipment, intellectual property, regulatory approvals, clinical data and all documentation related to TMR, for a purchase price of $1 million U.S. in cash, and the assumption of PLC's obligations under service contracts valued at approximately $700,000.

Completion of the acquisition is subject to the approval of PLC's shareholders at a special meeting of shareholders and is expected to close within 90 days.

Mark R. Tauscher, president and chief executive officer of PLC Systems Inc., stated, "We are very pleased to reach a positive agreement with Novadaq to purchase our TMR business. While this business is part of the foundation of PLC, its disposition enables PLC to focus entirely on our RenalGuard System™ operations.  In addition, the critical cash injection that this sale will provide us should enable us to continue to work on raising the additional funding we need to continue with our RenalGuard business. RenalGuard represents the future of PLC and we look forward to building upon the positive scientific data that were recently shared at the important TCT conference in late September. At the same time, we're confident that TMR customers will see no disruption in service since they are already working with Novadaq in many cases."

About PLC Systems Inc.

PLC Systems Inc. is a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Headquartered in Franklin, Massachusetts, PLC pioneered the CO2 Heart Laser System, which cardiac surgeons use to perform CO2 transmyocardial revascularization (TMR) to alleviate symptoms of severe angina.  PLC's newest product, RenalGuard, is approved for sale in the EU as a general fluid balancing device. Additional company information can be found at www.plcmed.com.

This press release contains "forward-looking" statements. For this purpose, any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "will" and similar expressions are intended to identify forward-looking statements. Our statements of our objectives are also forward-looking statements. While we may elect to update forward-looking statements in the future, we specifically disclaim any obligation to do so, even if our estimates change, and you should not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. Actual results could differ materially from those indicated by such forward-looking statements as a result of a variety of important factors, including that we may not obtain the required shareholder approval necessary for the sale of our TMR assets, other closing conditions to the proposed TMR asset sale transaction may not be met or other circumstances may occur prior to the anticipated closing that would result in this transaction not being concluded, we may be unable to raise capital necessary to continue our operations, we may not receive necessary regulatory approvals to market our RenalGuard product or that such approvals may be withdrawn,  the current  clinical trials in Italy and the planned future U.S. clinical trial for RenalGuard may not be completed in a timely fashion, if at all, or, if these clinical trials are completed, they may not produce clinically significant or meaningful results, the RenalGuard product may not be commercially accepted, operational changes, competitive developments may affect the market for our products, regulatory approval requirements may affect the market for our products, and additional risk factors described in the "Forward Looking Statements" section of our Annual Report on Form 10-K for the year ended December 31, 2009, and our other SEC reports.

PLC Systems, PLC Medical Systems, PLC, CO2 Heart Laser, RenalGuard and RenalGuard System are trademarks of PLC Systems Inc.

Novadaq is a trademark of Novadaq Technologies, Inc.

Contact:  Mary T. Conway

Conway Communications

617-244-9682

marytconway@comcast.net




'/>"/>
SOURCE PLC Systems Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mederi Therapeutics Announces Receipt of CE Mark for its Second Generation Secca® and Stretta® Systems
2. Varian Medical Systems Management to Present at Lazard Capital Markets 7th Annual Healthcare Conference
3. Saudi Arabias King Abdullah International Research Center Signs With Varian Medical Systems and IMRIS for Future Technology for Use in Radiotherapy
4. Varian Medical Systems to Supply Four Advanced Radiotherapy Treatment Machines to Global Hospitals in India
5. CURE Foundation Selects Varian Medical Systems to Supply Radiotherapy Technology for Five New Cancer Centers
6. Varian Medical Systems Reports Results for Fourth Quarter of Fiscal Year 2010
7. Opto Circuits Acquisition of Unetixs Vascular Creates Strong Synergies for Criticare Systems
8. Varian Medical Systems to Exhibit TrueBeam™ System for Image-Guided Cancer Treatments and New Software Capabilities at ASTRO Meeting in San Diego
9. Cardicas Automated Anastomosis Systems Featured at Advances In Robotic And Hybrid Coronary Revascularization Meeting
10. Delcath Systems Announces Third Quarter Progress Report Conference Call
11. Varian Medical Systems Schedules Webcast of Investor Meeting and Fiscal Year End Review at ASTRO in San Diego, November 2, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... 4, 2016 According to a ... Computer Interface Market - Global Industry Analysis, Size, Share, ... computer interface (BCI) market  is expected to reach a ... estimated to expand at a CAGR of 14.9 % ... A BCI device provides collaboration between the brain ...
(Date:5/4/2016)... upgrade. There are many medical recorders on the market but none like this. Through ...  offers unparalleled connectivity and functionality.  Ampronix  is a renowned authorized reseller of the medical ... Photo - http://photos.prnewswire.com/prnh/20160503/363416 ... ... ...
(Date:5/4/2016)... ZIONA, Israel , May 4, 2016 /PRNewswire/ ... announced today that BiondVax,s CEO, Dr. Ron Babecoff , ... New York City . On ... at Pioneers 2016, a conference presented by Joseph Gunner ... Hotel. The BiondVax presentation that Dr. Babecoff will ...
Breaking Medicine Technology:
(Date:5/4/2016)... Camas, WA (PRWEB) , ... ... ... Agencies, a full service insurance provider serving families of Camas and Vancouver, ... The current campaign fundraises for the National Breast Cancer Foundation and their ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... wellness and sleep disorder management, today announced it has secured $9 million in ... (WiL) and existing investors. The investment will be used by Somnoware to further ...
(Date:5/4/2016)... ... May 04, 2016 , ... Level 10 Head Over Heels Athletic ... to the University of Arizona for the fall of 2019. , After a ... Brovedani’s commitment to the GymCats came from her connection with the coaching staff and ...
(Date:5/4/2016)... York, NY (PRWEB) , ... May 04, 2016 ... ... largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the ... services – is set to return to the esteemed Quaker Ridge Golf Club ...
(Date:5/4/2016)... Boston, MA (PRWEB) , ... May 04, 2016 ... ... to help fund Dr. Todd Rider's research and development of DRACO broad-spectrum antiviral ... experiments. In the campaign that starts on May 3, 2016 at http://igg.me/at/EndTheVirus ...
Breaking Medicine News(10 mins):